HomeCompareNCBDF vs PFE

NCBDF vs PFE: Dividend Comparison 2026

NCBDF yields 1.57% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $22.0K in total portfolio value· pulled ahead in Year 9
10 years
NCBDF
NCBDF
● Live price
1.57%
Share price
$25.68
Annual div
$0.40
5Y div CAGR
24.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.1K
Annual income
$1,955.80
Full NCBDF calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — NCBDF vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNCBDFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NCBDF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NCBDF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NCBDF
Annual income on $10K today (after 15% tax)
$133.76/yr
After 10yr DRIP, annual income (after tax)
$1,662.43/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PFE beats the other by $21,466.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NCBDF + PFE for your $10,000?

NCBDF: 50%PFE: 50%
100% PFE50/50100% NCBDF
Portfolio after 10yr
$40.1K
Annual income
$14,583.17/yr
Blended yield
36.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

NCBDF
No analyst data
Altman Z
8.0
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NCBDF buys
0
PFE buys
0
No recent congressional trades found for NCBDF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNCBDFPFE
Forward yield1.57%6.20%
Annual dividend / share$0.40$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR24.6%13.2%
Portfolio after 10y$29.1K$51.1K
Annual income after 10y$1,955.80$27,210.54
Total dividends collected$7.8K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NCBDF vs PFE ($10,000, DRIP)

YearNCBDF PortfolioNCBDF Income/yrPFE PortfolioPFE Income/yrGap
1$10,896$196.08$9,161$701.38+$1.7KNCBDF
2$11,908$248.79$8,610$859.79+$3.3KNCBDF
3$13,058$316.60$8,366$1,081.25+$4.7KNCBDF
4$14,376$404.29$8,483$1,405.66+$5.9KNCBDF
5$15,901$518.32$9,084$1,907.24+$6.8KNCBDF
6$17,681$667.59$10,418$2,732.78+$7.3KNCBDF
7$19,783$864.46$13,007$4,193.56+$6.8KNCBDF
8$22,295$1,126.33$18,010$7,005.87+$4.3KNCBDF
9← crossover$25,333$1,478.08$28,216$12,979.89$2.9KPFE
10$29,062$1,955.80$51,081$27,210.54$22.0KPFE

NCBDF vs PFE: Complete Analysis 2026

NCBDFStock

BANDAI NAMCO Holdings Inc. develops entertainment-related products and services worldwide. Its Toys and Hobby segment offers toys, capsule and candy toys, cards, confectionery, food, apparel, sundries, plastic models, figures, communications and peripheral equipment, consumer electronics, character-based products, pachinko and pachislot machines, medical and electronic-related equipment, playground equipment, bicycles, furniture, visual, RC and robot toys, molds, stationery, prizes, and other products. This segment is also involved in the contract operations for inspecting and testing; and import and export of toys, etc. The company's Network Entertainment segment plans, develops, and distributes network content, as well as home video games, live events, machines, Internet-based online games, other software and services, amusement machines, etc.; and provides advertising, promotion, online video distribution and games platforms, communication and related tools, and shared services, as well as visual substrates. Its Real Entertainment segment plans, produces, and sells amusement machines; plans and operates amusement facilities, etc.; and provides after-sales services and stocks and sells pre-owned amusement machines and products. The company's Visual and Music Production segment offers visual and music content and package software, and audio engineering services; conducts live entertainment operations; plans and produces animation; manages affiliated artists; operates fan clubs; produces visual products related to live performances, events, and music; plans, produces, and sells goods, tickets, etc. Its IP Creation segment plans and produces animations, labels, events, etc., as well as music related to animations; manages and administers copyrights and other rights. The company was formerly known as NAMCO BANDAI Holdings, Inc. and changed its name to BANDAI NAMCO Holdings Inc. in June 2014. The company was founded in 2005 and is headquartered in Tokyo, Japan.

Full NCBDF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this NCBDF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NCBDF vs SCHDNCBDF vs JEPINCBDF vs ONCBDF vs KONCBDF vs MAINNCBDF vs JNJNCBDF vs MRKNCBDF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.